Use of economic evaluation guidelines: 2 years' experience in Canada.
Considerable effort has been expended in recent years in the development of methodology guidelines for economic evaluation of pharmaceutical products, driven in part by the desire to improve the rigour and quality of economic evaluations and to help decision making. Canada was one of the first countries to develop such guidelines and to encourage their use. This paper examines the extent to which the economic evaluations that were submitted to the Canadian Coordinating Office for Health Technology Assessment in the last two years adhered to Canadian guidelines. The analytic technique employed by twelve studies as well as the comparator used, the perspective taken, the outcome measure selected, the cost items that were taken into consideration and the extent of sensitivity analyses that were performed are reviewed in this paper. It can be concluded that although studies have been of variable quality, the majority of them were well presented, complete and transparent, due in part to the guidelines. Except for the perspective of the analysis, guidelines were, in many respects, adhered to and did not restrict investigators to specific methodologies or specific techniques. They were also instrumental in ensuring a minimum set of standards.
Baladi
J F
JF
Health Economics, Novartis Pharmaceuticals Canada Inc., Dorval, Quebec.
Menon
D
D
Otten
N
N
D002170:Canada; D003362:Cost-Benefit Analysis; D004341:Drug Evaluation / Q000379:methods*; D017850:Economics, Pharmaceutical; D017408:Guidelines as Topic; D006801:Humans; D018803:Models, Economic; D012680:Sensitivity and Specificity